Clinical Trial Update: Bortezomib, Ascorbic Acid, and Melphalan in Treating Patients With Newly Diagnosed Multiple Myeloma [Phase 2]

View source ↗

Summary

Phase 2 study evaluating the combination of bortezomib, ascorbic acid, and melphalan in newly diagnosed multiple myeloma patients. The trial status is completed…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma
• Plasma Cell Neoplasm

Drugs mentioned

• Alkeran (melphalan)
• Ascorbic acid (Vitamin C)
• Velcade (bortezomib)

Snippet

Sponsor: Oncotherapeutics | Conditions: Multiple Myeloma and Plasma Cell Neoplasm | Phase 2 | Status: COMPLETED